انتصار الدهون Fat victory (@hdh150) header
انتصار الدهون Fat victory (@hdh150) profile picture

Researcher in lipid chemistry

Joined February 2019
Photo by انتصار الدهون Fat victory (@hdh150)Photo by انتصار الدهون Fat victory (@hdh150)Photo by انتصار الدهون Fat victory (@hdh150)Photo by انتصار الدهون Fat victory (@hdh150)Photo by انتصار الدهون Fat victory (@hdh150)Photo by انتصار الدهون Fat victory (@hdh150)Photo by انتصار الدهون Fat victory (@hdh150)Photo by انتصار الدهون Fat victory (@hdh150)Photo by انتصار الدهون Fat victory (@hdh150)Photo by انتصار الدهون Fat victory (@hdh150)
الحمية الكيتونية تخفض الوزن رغم زيادة السعرات الحرارية فيها
Replying to @KenDBerryMD
Since someone is foolishly citing Kevin Hall's 2021 study against this post, here's what that study actually found. The people eating the animal-based ketogenic diet ate about 689 more calories a day than the low-fat group, so the idea that low-carb only works by cutting calories sure doesn't come from this paper. And insulin shutting down the release of stored fat from your fat cells isn't my theory, it's basic physiology in every textbook. @drterrysimpson? pubmed.ncbi.nlm.nih.gov/3347…
206
نظام الكيتو يقلل معدل النوبات القلبية إلى النصف
KETO CUTS HEART ATTACK RATE IN HALF Dr. Baker is right. This is the study that should end the keto heart attack scare. For 50 years doctors have warned that cutting carbs and eating more fat would give you a heart attack. This study checked what actually happened. 4,877 adults with type 2 diabetes or obesity cut their carbs with Virta. They were matched with 4,877 people on usual care. Heart attack, stroke or death: 4.1 per 1,000 people a year on low carb. 9.3 on usual care. Less than half. Study: pubmed.ncbi.nlm.nih.gov/4282… American Heart Ass’n CAVES on Low-Carb Diet! (KETO protects Heart) youtube.com/watch?v=2VhFIRxb…
1
3
372
فرضية الكوليسترول تسببت في الفوضى في صحة الإنسان وعطلت البحث في امراض الشرايين والقلب
The cholesterol hypothesis has been wreaking havoc on human health for 75 years. This is the idea that higher cholesterol levels, especially LDL, are causally linked to “clogged arteries” and heart disease. Let’s debunk once again:
1
286
تصلب الشرايين ينتج عن الجلكزة ( ضرر الجلكوز) . ويزداد سوءًا بفعل الالتهاب الناتج عن أكسدة زيوت البذور
Replying to @KenDBerryMD
Atherosclerosis is caused by glycosylation. It is worsened by inflammation driven by the oxidation of seed oils.
3
268
انتصار الدهون Fat victory retweeted
قلما اشوف احد يتكلم عن حمض اللينوليك ونواتج اكسدته بهالتفصيل.. طرح ممتاز ويستحق الاشادة. اللينوليك حمض دهني اساسي يحتاجه الجسم، لكن لمنع نقصه.. تكفي كميات قليلة حول 2% من السعرات اليومية. والفرق في تركيزه بين انواع الدهون كبير جدا.. شحم البقر فيه حوالي 3%، مقابل 53% في زيت الذرة و66% في زيت دوار الشمس. والدايت الغربي (اللي هو يشبه دايتنا)، وصلت نسبة اوميقا 6 الى اوميقا 3 فيه الى 20:1، وهي نسبة مرتفعة جدا. والمخاوف الصحية مو بس على الجلد.. في تجربة سيدني العشوائية، ارتفعت الوفيات القلبية في المجموعة اللي بدلت الدهون المشبعة بزيت العصفر (فيه 75% لينوليك) (17.2% مقابل 11%). وتجربة ثانية على 182 مصاب بالشقيقة، تقليل اللينوليك مع زيادة اوميقا 3 قلل ايام الصداع اكثر من زيادة اوميقا 3 لحالها. الاهتمام بمصادر اوميقا 3 (من المصادر الحيوانية) وتقليل استخدام زيوت البذور خطوة في الاتجاه الصحيح.. خصوصا مع قابلية هذه الزيوت للاكسدة. والأفضل اننا نستهدف نسبة 4:1 او اقل من اوميقا 6 الى 3. الرسم خذته من @insulin_resista
يمكن أن تؤثر الدهون و الزيوت التي نتناولها على الحكة وصحة الجلد، لكن التأثير ليس بسيطاً ولا ينطبق على كل الدهون بنفس الدرجة. دراسة (Wheeler وزملاؤه، المنشورة في Communications Biology عام 2026) تكشف آلية محتملة مهمة. حمض اللينوليك (حمض دهني أوميغا-6 شائع جداً في النظام الغذائي الغربي وفي الجلد) يمكن أن يتحول عند الأكسدة إلى مركبات مثل EKODE (9-keto-12,13-epoxy octadecenoic acid). هذا المركب يرتفع في مناطق إصابات الصدفية (خاصة تلك المصحوبة بحكة)، وعند حقنه في الفئران يثير سلوك الحك. الجديد في الدراسة أن EKODE يعمل كرابط قوي لمستقبل GPR35 على مجموعة من الخلايا العصبية الحسية في العقد الجذرية الظهرية. هذا التفعيل يؤدي إلى إطلاق النيوروببتيد Nppb (أو BNP) المرتبط بالحكة، ويساهم في الالتهاب وفرط الحساسية الحرارية. الحجب الجيني أو الدوائي لـ GPR35 قلل الحكة والالتهاب في نماذج فئران للصدفية (باستخدام إيميكويمود) والتهاب الجلد التأتبي. كما أن المستقبل موجود في خلايا عصبية بشرية أيضاً. ماذا يعني هذا عملياً؟ •ليست كل الدهون متساوية: حمض اللينوليك ضروري بكميات صغيرة، لكنه الأكثر وفرة في الجلد والنظام الغذائي الحديث. الزيوت العالية فيه (مثل عباد الشمس أو الذرة أو الصويا، غالباً 50-70% لينوليك) توفر مادة أولية أكبر لتكوين نواتج الأكسدة مثل EKODE في الظروف الالتهابية. زيت الزيتون البكر الممتاز منخفض نسبياً في اللينوليك (حوالي 10%) وغني بحمض الأوليك ومضادات الأكسدة. •السياق مهم: هذه النواتج تزداد خاصة في الجلد الملتهب أو تحت ضغط تأكسدي. النظام الغذائي الغربي المرتفع في أوميغا-6 مقارنة بأوميغا-3 يُناقش منذ سنوات لارتباطه بالالتهابات المزمنة. •الأدلة الحالية محدودة: الدراسة مخبرية ونماذج حيوانية + عينات خلايا بشرية. هي لا تثبت أن زيوت الطبخ “تسبب” الصدفية، ولا أن تقليلها أو استخدام زيت الزيتون “يعالجها” مباشرة. تحويل هذا إلى توصيات علاجية يحتاج دراسات سريرية بشرية. هناك أدلة أخرى داعمة لفكرة تأثير الدهون على الجلد. مثلاً، حمية البحر المتوسط (التي تعتمد على زيت الزيتون البكر الممتاز والأطعمة النباتية) أظهرت في تجربة عشوائية صغيرة تحسناً في شدة الصدفية الخفيفة إلى المتوسطة. الخلاصة التوعوية: الغذاء جزء من العناية بالجلد والصحة العامة، خاصة توازن الدهون وتقليل الأكسدة المفرطة. لكن الصدفية والحكة المزمنة حالات معقدة متعددة العوامل، ولا تغني عن المتابعة الطبية. الاكتشافات المخبرية مفيدة لفهم الآليات وتطوير علاجات مستقبلية (مثل استهداف GPR35)، لكنها ليست توصيات فورية لتغيير النظام الغذائي بشكل جذري.
1
2
7
1,185
انتصار الدهون Fat victory retweeted
اكلي بسيط لا تدور وصفات او افكار خرافية اللي اكله (وجبة باليوم) يكون يحتوي على واحد او اكثر من اللستة هذي: - سالمون مع زيت الزيتون، و5 بيضات بالزبدة. - دجاج على الفحم مع الجلد، ومعه طحينة وبصل احمر وصوص زبادي حار. - لحم مفروم مع 4 بيضات وسمن. - ستيك بالزبدة والسمن. - روبيان بالسمن. - لحم مفروم وخضار. - برقر لحم (من ماك) بدون خبز وبدون كتشب مع الجبن والصوص (مو دايم) واحيانا اضيف لبنة او ساور كريم او جبن او توتيات بكميات بسيطة. استهدف حول 150 قرام بروتين باليوم، والكربوهيدرات اخليها منخفضة قدر الامكان. بالاضافة لتمارين مقاومة وشوي كارديو
اكتبلي نظامك .. او انشر عل الصفحة العامة اكلك مال اسبوع كامل
1
21
2,188
في دراسة مراقبة كبيرة لأكثر من 150,000 امرأة بعد انقطاع الطمث، ارتبط استخدام الستاتين بنسبة 48% أعلى من خطر الإصابة بالسكري. وفي تجربة محكمة لمدة شهرين، رفع أتورفاستاتين الإنسولين الصائم بنسبة 25% إلى 45%
342
راجع تقرير 11 تجربة كبيرة للستاتينات قيست التأخير المتوسط في الوفاة على مدى سنتين إلى ست سنوات من العلاج. في الأشخاص الذين لم يعانوا بعد من نوبة قلبية أو سكتة دماغية، تأخرت الوفاة ببضعة أيام فقط. في الأشخاص الذين يعانون بالفعل من أمراض القلب، كان المتوسط 4.1 أيام
Statins delay death by only a few days, on average, in the trials that tested them. These drugs are widely prescribed to lower LDL cholesterol and to reduce the chance of a heart attack or stroke. Yet for most people taking them, the absolute benefit is small, and the outcome that matters most, living longer, is where the trial data are thinnest. A review of 11 large statin trials measured the average delay in death over two to six years of treatment. In people who had not yet had a heart attack or stroke, death was delayed by only a few days. In people who already had heart disease, the median was 4.1 days, and some trials showed slightly shorter survival on the drug. And that is an average, so many people gained nothing at all. Muscle symptoms are commonly reported by people taking these drugs. In an observational study of people on high-dose statin therapy, about 1 in 10 reported muscle symptoms, and some surveys put that share closer to 1 in 4. In a large observational study of more than 150,000 postmenopausal women, statin use was linked to a 48% higher risk of developing diabetes. In a two-month controlled trial, atorvastatin raised fasting insulin by 25% to 45%. A person weighing a few extra days of life against muscle pain and a higher diabetes risk deserves to see those numbers side by side.
284
كنت الافضل لياقة ارقامي جيدة من كولستيرول وغيره اذا كانت هذه الحجج لم تفسر سبب اصابتي بأزمة قلبية لماذا لا اختبر الإدعاءات الاخرى من التهابات مزمنة ومقاومة انسولين اليس هذا في مصلحتي ام ان القضية ليست مصلحة المريض
I was the fittest patient in the cath lab. So why did no one ask how my body handled sugar? Sunrise in London. I'm here building Neo in the UK, and the gym is where I think best. At 52 I had trained my whole life. My cholesterol was "fine." The doctors who saved me were good people, and they did their job well. But here's the question I still haven't had answered. If my number was fine and my fitness was elite, what was the test that would have warned me? Not one person asked about my insulin. Not one asked about the inflammation in my artery wall. The system is built to treat the event, not to find the cause. I ask people in London about fasting insulin and no-one knows about this. That is about to change in a big with Neo UK launch Jan 2027 Six years later I still train every morning. Zero meds. Ask your doctor this week: what did my last panel tell you about my metabolism? Then listen to the answer.
1
4
524
الغذاء المخمر ادى الى ارتفع تنوع بكتريا الأمعاء وانخفاض 19 بروتينًا التهابيًا
Stanford put 36 healthy adults on one of two diets for 10 weeks. High fiber, or high fermented foods like yogurt, kimchi and kefir. Fermented group: gut diversity climbed, 19 inflammatory proteins dropped. Fiber group: diversity didn’t budge. I show the 3 moves I’d start with 👇 youtube.com/watch?v=XmwLcwU5… via @YouTube
3
109
6,888
هذا الأسبوع، أعلنت نوفارتيس أن دواءها pelacarsen، الذي يقلل Lp(a) بنسبة 80%، فشل في تقليل النوبات القلبية أو السكتات الدماغية أو الوفيات القلبية في 8,323 مريضًا تم متابعتهم لسبع سنوات
I have been saying for months that Lp(a) is a genetic risk factors for heart disease. It promotes clotting, carries oxidized phospholipids into the vessel wall, and drives plaque independently of LDL. I still believe that. Knowing your Lp(a) changes every decision you make about your health. This week, Novartis announced that their drug pelacarsen, which cut Lp(a) by 80%, failed to reduce heart attacks, strokes, or cardiac deaths in 8,323 patients followed for seven years. "This is a huge blow," said the president of the American Society for Preventive Cardiology. These are educated doctors. That is what makes this worse. They are not shocked because the science failed. They are shocked because their assumption failed. The assumption that moving one number with one drug would change the outcome. The same assumption that has failed with HDL drugs, CETP inhibitors, and IL-6 blockers. Every time a drug lowers a marker and the disease does not move, they are stunned. Every single time. At some point, shock is no longer the right response. The right response is to question the framework. But here is why they do not question it. There is no money in the answer. The sick care system does not profit from a patient who heals through food and lifestyle. It profits from a patient who stays on a drug for the rest of their life. A patient who addresses the root cause and no longer needs a prescription is a cancelled subscription. A patient who takes a monthly injection for 30 years is recurring revenue. Novartis said the Lp(a) market could be worth more than five billion dollars a year. That is not a medical hypothesis. That is a business plan. And when the business plan fails, the shock is not scientific. It is financial. Nobody is funding a trial that tests whether whole food, movement, stress management, and sleep can do what pelacarsen could not. Not because the idea is unscientific. Because there is no patent on food. There is no monthly injection for walking. There is no five billion dollar market for telling a patient to fix their environment. The marker is not the disease. It never was. You can silence the signal with a drug. The alarm stops ringing. The house is still on fire. The insulin resistance is still there. The chronic inflammation is still there. The oxidative stress is still there. The vessel wall is still under attack from twelve directions. You cannot fight a twelve-headed dragon by cutting off one head with a pill. You have to change the environment that is feeding all twelve heads at once. That is root cause medicine. That is what I am building. And that is what the sick care system will never fund, because a healthy patient is the one thing it was not designed to produce. The truth heals
1
5
659
نظام الكربوهيدرات المنخفضة / الدهون المشبعة العالية: اعطى 👉 أكبر انخفاض في مستوى السكر في الدم 👉 أكبر انخفاض في دهون الكبد 👉 أكبر انخفاض في LP-IR (7 أضعاف ذلك للنباتي) 👉 نفس انخفاض LDL وApoB مثل النباتي
The American Heart Association recommends getting no more than 6% of your Calories from saturated fat. A 6-month, weight-loss-controlled randomized trial found that a ketogenic diet with 23% of Calories from saturated fat produced better cardiometabolic benefits than a Mediterranean or low-fat plant-based diet in people with obesity. Low-carb / High-Sat fat diet had: 👉 Largest drop in blood sugar 👉 Largest drop in liver fat 👉 Largest drop in LP-IR (7x that of plant-based) 👉 Same LDL and ApoB drop as plant-based How evidence-based are the AHA's recommendations? For a nuanced deep dive, see today's letter on reversing fatty liver (3/3 in 🧵👇)
9
1,290
الناتوكيناز قلّصت اللويحات في الشرايين المسدودة بنسبة 36% في دراستين بشريتين. دراستان منفصلتان، نتائج شبه متطابقة. الجرعة حاسمة: يجب أن تكون على الأقل 6,000 وحدة FU/يوم لتقليص لويحات الشرايين. الجرعات المنخفضة من 2,000–3,600 وحدة FU/يوم كانت غير فعالة.
Nattokinase SHRANK PLAQUE in clogged arteries by 36% in TWO human studies. Two separate studies, nearly IDENTICAL results. The dose is critical: at least 6,000 FU/day was needed to shrink arterial plaque. Lower doses of 2,000–3,600 FU/day were ineffective.
1
7
640
STATINS CUT YOUR GLP-1 IN HALF GLP-1 is a hormone your own gut makes every time you eat. It tells your body you're full and helps you handle sugar. The Ozempic/Wegovy shots are a weak copy of it. In a 16-week human trial, people on atorvastatin saw their active GLP-1 fall from 5.18 to 2.65 pg/mL. That's about a 49% drop. If your blood sugar has crept up since you started a statin, bring it up with your doctor. Don't stop any medicine on your own, but ask if you still need it, and ask for a fasting insulin test. Sources below.
1
353
ثلاث دراسات تجمع على ان ال دي ال ليس هو المحدد للازمات القلبية
Kalp hastalıkları söz konusu olduğunda ilk sorgulanan ve ilaçlarla düşürülmeye çalışılan değer genellikle LDL kolesterol oluyor. Peki kalp-damar sağlığını yalnızca LDL üzerinden değerlendirmek ne kadar doğru? Bu konuda üç önemli araştırma dikkat çekiyor. 1. Yaklaşık 96 bin kişinin 10 yıl takip edildiği çalışmada, trigliserit yüksekliğiyle ilişkili trigliserit/HDL oranının, kardiyovasküler hastalık riskini öngörmede LDL kolesterolden daha iyi bir gösterge olduğu bulundu. Kolesterolün büyük bölümü vücutta sentezlenirken trigliserit düzeyleri özellikle unlu ve şekerli beslenmeden, fazla karbonhidrat tüketiminden ve insülin direncinden belirgin biçimde etkileniyor. Trigliserit yüksekliği, özellikle düşük HDL ile birlikte olduğunda, insülin direncinin ve metabolik bozulmanın önemli göstergelerinden biri. 2. Güney Kore’de yaklaşık 15 milyon kişinin ortalama 8,8 yıl takip edildiği çalışmada LDL kolesterol ile kardiyovasküler ölüm arasında U şeklinde bir ilişki bulundu. En düşük kardiyovasküler ölüm riski, en düşük LDL seviyelerinde değil, 90–149 mg/dL aralığında gözlendi. Yani daha düşük LDL, her zaman daha düşük kardiyovasküler ölüm riskiyle ilişkili değildi. Bu gözlemsel çalışma, LDL’nin tek başına kardiyovasküler ölümün nedeni olduğunu da göstermiyor. 3. 2026’da yayımlanan AMUNDSEN adlı randomize çalışmada kalp krizi geçirmiş 2.161 hastada, standart kolesterol tedavisine eklenen evolocumab ile LDL kolesterol 16 mg/dL’ye kadar düşürüldü. Ancak bir yıllık takipte ölüm veya plansız kardiyovasküler hastaneye yatış açısından anlamlı bir ek klinik fayda gösterilemedi. Bu üç çalışma bize önemli bir noktayı hatırlatıyor: LDL kolesterolü kalp-damar hastalıklarının tek belirleyicisi gibi görmek yerine, onu daha geniş bir metabolik tablonun içinde değerlendirmek daha doğru olabilir. Bazı hastalarda LDL yüksekliği, tek başına bağımsız bir risk faktörü olmasının yanında, insülin direnci ve metabolik bozukluklarla birlikte görülen bir bulgu da olabilir. Dolayısıyla kardiyovasküler risk ile LDL arasındaki her istatistiksel ilişkiyi doğrudan nedensellik olarak yorumlamamak gerekir. Beslenme şekli, özellikle unlu ve şekerli gıdaların fazla tüketilmesi, insülin direnci, trigliserit yüksekliği ve metabolik sağlığın en önemli mesele olduğu unutulmamalı.
2
6
751
جميع الكائنات الحية الفقارية تنتج LDL في أجسامها منذ حوالي 500 مليون سنة. ولأسباب غامضة، في الطبيعة بأكملها، تم اعتبار LDL للبشر فقط "مشكلة"، أي "الكوليسترول السيء"،ك حسنًا، لماذا؟ لأن شركة أدوية عملاقة اشترت في عام 1987 براءة اختراع لجزيء خافض للكوليسترول من اليابانيين
Işıl Hanım, Tüm omurgalı canlılar yaklaşık 500 milyon yıldır vücutlarında LDL üretiyor. Ne hikmetse, koca doğada bir tek insan soyunun LDL’si "sorunlu" yani “kötü kolesterol” olarak görüldü ve sadece bizimkinin düşürülmesi gerektiği iddia edildi! Peki neden? Çünkü 1987 yılında dev bir ilaç firması, kolesterol düşürücü bir molekülün patentini Japonlardan satın aldı. Ardından uyduruk, pahalı ve "bilimsel" süsü verilmiş araştırmalarla kardiyologlar manipüle edildi. Bugün milyonlarca insana bu ilaçların yazılmasının tek sebebi, işte bu küresel firmaların milyar dolarlık cirolarını korumaktır.
1
8
1,226
رئيس وزراء الهند يذهب إلى الإذاعة الوطنية ليطلب من الناس استخدام كمية أقل من زيت الطهي نظراً للتدهور الصحي الذي سببه لهم
India, the most vegetarian nation on earth, now has a Prime Minister going on national radio to beg it to use less cooking oil. In February 2025 Narendra Modi used his monthly broadcast to ask every family to cut its edible oil by 10%, and to pass the challenge on to ten others. By August he was repeating it in his Independence Day speech. The national school board told schools to put up oil boards, and the health ministry wanted signs in offices showing how much oil is in a samosa. He had reason. In 2022, 212 million Indians had diabetes, more than a quarter of every diabetic on the planet, and 133 million of them weren't being treated. He warned the country it could have 440 million obese people by 2050. It starts before birth. Doctors in Pune found Indian newborns were the best part of a kilo lighter than British ones, and had lost far less of their fat than of everything else. They named it the thin-fat baby. This is the nation that eats around 8kg of meat a head a year, a fraction of the world average. The plate is rice, roti, dal and vegetables, as approved by every plant-based book in print. And the fat it is cooked in stopped being ghee a long time ago. India is the biggest importer of edible oil on earth, and the tins on the kitchen shelf hold soybean, sunflower and palm. A country that eats a fraction of the world's meat and swapped its ghee for the imported tins has ended up with a quarter of the world's diabetes. It is still cited as proof that the plants work. The ghee was never the problem, India. Put it back in the pan.
285
شخصان بمستويات ApoB متطابقة. نتائج مختلفة تمامًا. الفرق هو ما إذا كان HDL يعمل أم معطل. ما الذي يعطل وظيفة HDL؟ الخلل الأيضي. نفس مقاومة الأنسولين والالتهاب المزمن اللذين يضرانان بجدار الوعاء يعيقان أيضًا النظام المصمم لحمايته
Replying to @SBakerMD
I have been saying this for months. It is not the particle. It is the environment the particle enters. Two people with identical ApoB levels. Completely different outcomes. The difference is whether HDL is functioning or broken. What breaks HDL function? Metabolic dysfunction. The same insulin resistance and chronic inflammation that damages the vessel wall also impairs the system meant to protect it. Fix the environment. The rest follows.
4
633
عندما يكون HDL-C مرتفعًا ... يتلاشى تأثير ارتفاع apoB" ملاحظة: نظام غذائي منخفض الكربوهيدرات يزيد من HDLc بقوة
Is high LDL cholesterol (or apoB) harmful ONLY with poor metabolic health, characterized by low HDLc? New study from preeminent lipidologist Sniderman: "when HDL-C is high ... effect of changing apoB vanishes" PS: A low-carb diet potently increases HDLc academic.oup.com/eurjpc/adva…
1
334
دكتور كين: كيف يفسرون هذا؟ لقد أُخبرتَ أن ارتفاع الكوليسترول سيضعك في قبر مبكر. دراسة سويدية شملت 44,636 شخصًا وجدت أن الذين عاشوا حتى 100 عام لديهم كوليسترول أعلى. لماذا؟
How do they explain this one? You've been told high cholesterol will put you in an early grave. A Swedish study of 44,636 people found the ones who lived to 100 had higher cholesterol. Why? Read on... Researchers in Sweden drew blood on 44,636 people aged 64 to 99 and followed them for up to 35 years. 1,224 of them lived to see their 100th birthday. The people who made it to 100 had higher total cholesterol and higher iron. They had lower glucose, lower creatinine, and lower uric acid. The authors wrote that the cholesterol finding "stands in contrast to clinical guidelines regarding cholesterol levels." Those are their words, not mine. This was an observational study, so it can't prove cholesterol made anybody live longer. But it does not fit the story that higher cholesterol means you die young. The number that pointed the wrong way was blood sugar. Few doctors check for hyperinsulinemia, so ask your doctor for a fasting insulin test. The Study and my videos below...
3
789